Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | KHK | P50053 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MPI | P34949 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31039595 | 1.00 | MEN1 (0.51) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL9926877 | 0.87 | RAB9A (0.51) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL29368311 | 0.85 | MAPT (0.55) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL24543271 | 0.85 | MAPT (0.55) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL6298255 | 0.82 | MEN1 (0.48) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL30725849 | 0.81 | MAPT (0.57) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL29741029 | 0.81 | MAPT (0.43) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL15797001 | 0.79 | KHK (0.51) | RAB9ANPC1MAPTFGFR1HPGD | |
| SCHEMBL29741246 | 0.79 | GLS (0.39) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL5382099 | 0.78 | RAB9A (0.50) | MEN1KMT2ARAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3676255-B1 | THERAPEUTIC INDAZOLES | RUTGERS THE STATE UNIV UNIV OF NEW JERSEY (US) | 2025-04-16 | — | — | EP | disclosed |
| US-12060330-B2 | Therapeutic indazoles | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-08-13 | — | — | US | disclosed |
| US-20220144781-A1 | THERAPEUTIC INDAZOLES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-05-12 | — | — | US | disclosed |
| US-11186549-B2 | Therapeutic indazoles | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-11-30 | — | — | US | disclosed |
| CN-111479805-A | Therapeutic indazoles | 罗格斯新泽西州立大学 | 2020-07-31 | — | — | CN | disclosed |
| US-20200199076-A1 | THERAPEUTIC INDAZOLES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-06-25 | — | — | US | disclosed |
| EP-2081910-B1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-7947727-B2 | Compounds | GlaxoGroupLimited (GB) | 2011-05-24 | — | — | US | disclosed |
| US-20100120883-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060330-B2 | Therapeutic indazoles | RIF1, QTRT1, NQO2 | MEN1 1008/4885KMT2A 3560/4885RAB9A 1080/4885 |
| US-20100120883-A1 | NOVEL COMPOUNDS | TSLP, LTB4R2, LTB4R | MEN1 4416/4885KMT2A 4335/4885RAB9A 3357/4885 |
| US-20220144781-A1 | THERAPEUTIC INDAZOLES | RIF1, QTRT1, NQO2 | MEN1 1008/4885KMT2A 3560/4885RAB9A 1080/4885 |
| US-20200199076-A1 | THERAPEUTIC INDAZOLES | RIF1, NQO2, QTRT1 | MEN1 1010/4885KMT2A 3462/4885RAB9A 1255/4885 |
| US-11186549-B2 | Therapeutic indazoles | RIF1, NQO2, QTRT1 | MEN1 1010/4885KMT2A 3462/4885RAB9A 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.